¼¼°èÀÇ Ã¶ °áÇÌÁõ ÁÖ»çÁ¦ ½ÃÀå º¸°í¼­(2025³â)
Iron Deficiency Injectable Global Market Report 2025
»óǰÄÚµå : 1691978
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 200 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,371,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,209,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 12,048,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ö °áÇÌÁõ ÁÖ»çÁ¦ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â µ¿¾È ºü¸£°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2029³â±îÁö 10.8%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)·Î 231¾ï 3,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ¼ºÀåÀº °í·É Àα¸, ¼¼°è º¸°Ç¿¡ ´ëÇÑ ³ë·Â, Á¤ºÎÀÇ ³ë·Â, ¸¸¼ºÁúȯ¿¡ ´ëÇÑ Ä¡·á Áõ°¡, ±Þ¼ÓÇÑ Ã¶ºÐ º¸Ãæ µî¿¡ ±âÀÎÇÏ´Â °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾È ÁÖ¿ä µ¿ÇâÀ¸·Î´Â öºÐÁ¦Á¦ÀÇ ¹ßÀü, µðÁöÅÐ °Ç°­ ¼Ö·ç¼Ç, ö °áÇÌÁõ ÁÖ»çÁ¦ Ä¡·áÀÇ ¹ßÀü, öºÐ ±â¹Ý ¾à¹°ÀÇ Ã¤Åà µîÀÌ ÀÖ½À´Ï´Ù.

ö °áÇÌÁõ ÁÖ»çÁ¦ ½ÃÀåÀº ´Ù³¶¼º³­¼ÒÁõÈıº(PCOS)ÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇØ ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. PCOS´Â ÁÖ·Î °¡Àӱ⠿©¼ºÀÇ ³­¼Ò¸¦ °¡Áø °³Àο¡°Ô ¿µÇâÀ» ¹ÌÄ¡´Â ÈçÇÏ°Ô ¹ß»ýÇϴ ȣ¸£¸ó ÀÌ»óÀ¸·Î, Á¾Á¾ öºÐ °ú´ÙÁõÀ» À¯¹ßÇÏ¿© ¿ù°æ °ú´Ù ÃâÇ÷°ú ºóÇ÷À» À¯¹ßÇÕ´Ï´Ù. ÁÖ»ç¿ë öºÐ °áÇÌ Ä¡·áÁ¦´Â ÀÌ ÁúȯÀ» Ä¡·áÇÒ ¼ö ÀÖ´Â È¿°úÀûÀÎ ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹¿¡ º»ºÎ¸¦ µÐ º¸°Ç Àü¹® ±â°üÀÎ ¼¼°èº¸°Ç±â±¸(WHO)´Â 2023³â 6¿ù ÇöÀç Àü ¼¼°è °¡Àӱ⠿©¼ºÀÇ ¾à 8-13%°¡ ´Ù³¶¼º³­¼ÒÁõÈıºÀ» ¾Î°í ÀÖÀ¸¸ç, ±× Áß 70%°¡ ¹ÌÁø´Ü »óÅ·Π³²¾Æ ÀÖ´Â °ÍÀ¸·Î ÃßÁ¤Çϰí ÀÖ½À´Ï´Ù. µû¶ó¼­ ´Ù³¶¼º³­¼ÒÁõÈıº(PCOS)ÀÇ À¯º´·ü Áõ°¡´Â ö °áÇÌÁõ ÁÖ»çÁ¦ ½ÃÀåÀÇ ¼ºÀå µ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¿µ¾ç½ÇÁ¶ÀÇ »ó´çÇÑ È®»êÀº ö °áÇÌÁõ ÁÖ»çÁ¦ ½ÃÀå È®´ëÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀÔ´Ï´Ù. ¿µ¾ç½ÇÁ¶´Â Çʼö ¿µ¾ç¼Ò ¼·Ãë·®°ú ½ÅüÀÇ ¿µ¾ç ¿ä±¸·® »çÀÌÀÇ ºÒ±ÕÇüÀ» Ư¡À¸·Î ÇÏ´Â °Ç°­ »óŸ¦ ÀǹÌÇÕ´Ï´Ù. ö °áÇÌÁõ ÁÖ»çÁ¦´Â öºÐ ÀúÀå·®À» ½Å¼ÓÇÏ°Ô º¸ÃæÇϰí Ç÷·ù¿¡ ½±°Ô Èí¼öµÇ´Â öºÐÀ» ÁýÁßÀûÀ¸·Î Åõ¿©ÇÏ¿© °áÇÌÁõÀ» ½Å¼ÓÇÏ°Ô °³¼±ÇÏ¿© ¿µ¾ç½ÇÁ¶¿¡ ´ëóÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 3¿ù ͏®Æ÷´Ï¾ÆÁÖ °øÁߺ¸°Ç±¹Àº 2022³â ¿µ¾ç½ÇÁ¶ °ü·Ã »ç¸ÁÀÚ ¼ö°¡ 1,406¸íÀ¸·Î Áõ°¡Çß´Ù°í º¸°íÇßÀ¸¸ç, ÀÌ´Â 2021³â ±â·ÏµÈ »ç¸ÁÀÚ ¼ö 1,149¸í¿¡ ºñÇØ 22.36%³ª ±ÞÁõÇÑ ¼öÄ¡ÀÔ´Ï´Ù. ±× °á°ú, ¿µ¾ç½ÇÁ¶ À¯º´·üÀÇ Áõ°¡´Â ö °áÇÌÁõ ÁÖ»çÁ¦ ½ÃÀåÀÇ ÇâÈÄ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, Äڷγª, ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°¡¤±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷°ú Çõ½ÅÀû ±â¾÷

Á¦32Àå ¼¼°èÀÇ ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´

Á¦34Àå ÃÖ±ÙÀÇ ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀå ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Iron deficiency refers to a condition where the body lacks adequate iron, leading to decreased production of red blood cells and hemoglobin. Iron deficiency injectables refer to injectable medications or solutions used to treat iron deficiency. These injectable forms of iron allow for direct delivery of the iron into the bloodstream, bypassing the digestive system.

The main types of iron deficiency injectables are iron dextran, iron sucrose and ferric carboxymaltose. Iron dextran is a complex of iron and a carbohydrate called dextran. The various types of branded or generics are branded, generics that are used in various applications such as chronic kidney disease, inflammatory bowel disease, cancer and others and also by various end users such as hospitals, homecare, specialty clinics and others.

The iron deficiency injectables market research report is one of a series of new reports from The Business Research Company that provides iron deficiency injectables market statistics, including iron deficiency injectables industry global market size, regional shares, competitors with an iron deficiency injectables market share, detailed iron deficiency injectables market segments, market trends and opportunities and any further data you may need to thrive in the iron deficiency injectables industry. This iron deficiency injectables market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The iron deficiency injectable market size has grown strongly in recent years. It will grow from $14.06 billion in 2024 to $15.37 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to high prevalence of iron deficiency anemia treatments, bariatric surgery patients, pediatric and adolescent patients, growing pregnancy.

The iron deficiency injectable market size is expected to see rapid growth in the next few years. It will grow to $23.13 billion in 2029 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to geriatric population, global health initiatives, government initiatives, incresing treatments for chronic conditions, rapid iron replenishment. Major trends in the forecast period include advances in iron formulations, digital health solutions, advancements in iron deficiency injectable therapy, adoption of iron-based drugs.

The iron deficiency injectables market is anticipated to experience growth due to the increasing prevalence of polycystic ovary syndrome (PCOS). PCOS is a commonly occurring hormonal disorder that predominantly affects individuals with ovaries, primarily women in their reproductive years. PCOS often leads to iron overload, resulting in excessive menstrual bleeding and subsequent anemia in affected patients. Injectable iron deficiency medications offer an effective solution to address this condition. For example, as of June 2023, the World Health Organization, a specialized health agency based in the United States, estimates that PCOS affects approximately 8-13% of reproductive-aged women globally, with 70% of cases remaining undiagnosed. Hence, the rising prevalence of polycystic ovary syndrome (PCOS) serves as a driving force behind the growth of the iron deficiency injectables market.

The substantial prevalence of malnutrition is a key driver behind the expansion of the iron deficiency injectable market. Malnutrition signifies a health condition marked by an imbalance between the intake of essential nutrients and the nutritional requirements of the body. Iron deficiency injectables play a crucial role in addressing malnutrition by swiftly replenishing iron stores and delivering a concentrated dose of iron that is readily absorbed into the bloodstream, enabling the rapid correction of the deficiency. For example, in March 2023, the California Department of Public Health reported an increase in malnutrition-related deaths to 1,406 in 2022, marking a notable 22.36% surge compared to the 1,149 deaths recorded in 2021. As a result, the heightened prevalence of malnutrition is expected to drive the future growth of the iron deficiency injectable market.

Prominent companies operating in the iron deficiency injectables market are actively engaged in the development of innovative therapies, such as INJECTAFER, to maintain their competitive standing in the market. For instance, in June 2023, Daiichi Sankyo Company, a U.S.-based healthcare company, in collaboration with American Regent Inc., a U.S.-based injectables manufacturer, introduced INJECTAFER (ferric carboxymaltose injection) for the treatment of iron deficiency. This innovative therapy received approval from the Food and Drug Administration (FDA), a U.S. government agency. INJECTAFER is recognized as the first and only intravenous iron replacement therapy approved for adult patients with chronic and progressive heart failure. It has undergone rigorous evaluation through more than 40 clinical trials involving over 8,800 participants from various countries, demonstrating its effectiveness in patients, including adults and pediatric individuals with iron-deficient anemia and heart failure.

In August 2022, CSL Limited, an Australian-based biotechnology company specializing in the production of iron deficiency injectables, completed the acquisition of Vifor Pharma for an undisclosed sum. This strategic acquisition reinforces CSL's commitment to patient care and enhances its capability to provide advanced medications. Vifor Pharma, headquartered in Switzerland, is a pharmaceutical company renowned for its offerings in the field of iron deficiency injectables.

Major companies operating in the iron deficiency injectable market are Daiichi Sankyo Company Limited, Pfizer Inc., Aetna Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A, AstraZeneca PLC, GSK PLC, Fresenius Medical Care, Teva Pharmaceutical Industries Ltd., Mylan N.V., B Braun Medical Inc., Sandoz, Fresenius Kabi AG, Cipla Limited, Emcure Pharmaceuticals Ltd., AMAG Pharmaceuticals Inc., Luitpold Pharmaceuticals Inc., Akebia Therapeutics Inc., Covis Pharma GmbH, Keryx Biopharmaceuticals Inc., Rockwell Medical Inc., American Regent Inc., Galen Medical Group.

North America was the largest region in the iron deficiency injectable market in 2024. The regions covered in iron deficiency injectable report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the iron deficiency injectable market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The iron deficiency injectable market consists of sales of ferumoxide, sodium ferric gluconate and iron gluconate. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Iron Deficiency Injectable Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on iron deficiency injectable market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for iron deficiency injectable ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The iron deficiency injectable market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Iron Deficiency Injectable Market Characteristics

3. Iron Deficiency Injectable Market Trends And Strategies

4. Iron Deficiency Injectable Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Iron Deficiency Injectable Growth Analysis And Strategic Analysis Framework

6. Iron Deficiency Injectable Market Segmentation

7. Iron Deficiency Injectable Market Regional And Country Analysis

8. Asia-Pacific Iron Deficiency Injectable Market

9. China Iron Deficiency Injectable Market

10. India Iron Deficiency Injectable Market

11. Japan Iron Deficiency Injectable Market

12. Australia Iron Deficiency Injectable Market

13. Indonesia Iron Deficiency Injectable Market

14. South Korea Iron Deficiency Injectable Market

15. Western Europe Iron Deficiency Injectable Market

16. UK Iron Deficiency Injectable Market

17. Germany Iron Deficiency Injectable Market

18. France Iron Deficiency Injectable Market

19. Italy Iron Deficiency Injectable Market

20. Spain Iron Deficiency Injectable Market

21. Eastern Europe Iron Deficiency Injectable Market

22. Russia Iron Deficiency Injectable Market

23. North America Iron Deficiency Injectable Market

24. USA Iron Deficiency Injectable Market

25. Canada Iron Deficiency Injectable Market

26. South America Iron Deficiency Injectable Market

27. Brazil Iron Deficiency Injectable Market

28. Middle East Iron Deficiency Injectable Market

29. Africa Iron Deficiency Injectable Market

30. Iron Deficiency Injectable Market Competitive Landscape And Company Profiles

31. Iron Deficiency Injectable Market Other Major And Innovative Companies

32. Global Iron Deficiency Injectable Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Iron Deficiency Injectable Market

34. Recent Developments In The Iron Deficiency Injectable Market

35. Iron Deficiency Injectable Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â